Gotte and collaborators [118] noted a relationship between intensity of syndecan-1 immunostaining in pre-chemotherapy breast cancer biopsies and decreased response to treatment with cyclophosphamide and cisplatin. Here, SDC1 is linked to breast carcinoma.